1. Home
  2. CGC vs XOMAP Comparison

CGC vs XOMAP Comparison

Compare CGC & XOMAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGC
  • XOMAP
  • Stock Information
  • Founded
  • CGC N/A
  • XOMAP N/A
  • Country
  • CGC Canada
  • XOMAP United States
  • Employees
  • CGC N/A
  • XOMAP 13
  • Industry
  • CGC Pharmaceuticals and Biotechnology
  • XOMAP Biotechnology: Pharmaceutical Preparations
  • Sector
  • CGC Health Care
  • XOMAP Health Care
  • Exchange
  • CGC Nasdaq
  • XOMAP Nasdaq
  • Market Cap
  • CGC N/A
  • XOMAP N/A
  • IPO Year
  • CGC N/A
  • XOMAP N/A
  • Fundamental
  • Price
  • CGC $6.50
  • XOMAP $25.90
  • Analyst Decision
  • CGC Sell
  • XOMAP
  • Analyst Count
  • CGC 2
  • XOMAP 0
  • Target Price
  • CGC $4.30
  • XOMAP N/A
  • AVG Volume (30 Days)
  • CGC 2.5M
  • XOMAP N/A
  • Earning Date
  • CGC 08-07-2024
  • XOMAP N/A
  • Dividend Yield
  • CGC N/A
  • XOMAP N/A
  • EPS Growth
  • CGC N/A
  • XOMAP N/A
  • EPS
  • CGC N/A
  • XOMAP N/A
  • Revenue
  • CGC $218,489,706.00
  • XOMAP N/A
  • Revenue This Year
  • CGC $3.59
  • XOMAP N/A
  • Revenue Next Year
  • CGC $5.90
  • XOMAP N/A
  • P/E Ratio
  • CGC N/A
  • XOMAP N/A
  • Revenue Growth
  • CGC N/A
  • XOMAP N/A
  • 52 Week Low
  • CGC $2.76
  • XOMAP N/A
  • 52 Week High
  • CGC $19.20
  • XOMAP N/A
  • Technical
  • Relative Strength Index (RSI)
  • CGC 40.76
  • XOMAP 57.20
  • Support Level
  • CGC $6.07
  • XOMAP $25.31
  • Resistance Level
  • CGC $6.41
  • XOMAP $25.80
  • Average True Range (ATR)
  • CGC 0.33
  • XOMAP 0.30
  • MACD
  • CGC 0.07
  • XOMAP -0.02
  • Stochastic Oscillator
  • CGC 40.19
  • XOMAP 57.08

About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Share on Social Networks: